植物生物反应器生产异源蛋白

利用植物表达系统生产外源蛋白是一个有吸引力的廉价生产系统 ,它有可能替代外源蛋白的发酵生产系统。本文对分子农业的意义、植物表达外源蛋白的影响因素和植物生产外源蛋白质的研究进展等方面作了论述     

Asia-Ⅰ口蹄疫病毒P1-2A基因真核表达质粒的构建及小鼠免疫试验

目的 构建含有Asia-Ⅰ型口蹄疫病毒(FMDV)衣壳蛋白前体P1-2A 基因的真核表达质粒pVAXⅠ-P1-2A,并用pVAXⅠ-P1-2A免疫小鼠,评价其体液免疫和细胞免疫水平。方法 通过RT-PCR 方法扩增得到含有FMDV P1-2A编码区的目的基因,并将其克隆到pMD18-T载体上。将pMD18-T-P1-2A和 pVAXⅠ分别经EcoRⅤ和XbaⅠ双酶切后连接构建真核表达质粒pVAXⅠ-P1-2A。将酶切鉴定正确后的重组质粒转染HeLa细胞进行IFA检测。再进行小鼠血清特异性抗体试验、小鼠T淋巴细胞增殖试验和IFN-γ ELISPOT试验。结果 酶切结果与预期目的条带大小相符;荧光结果表明经pVAXⅠ-P1-2A转染的细胞有明显的黄绿色荧光,说明P1-2A基因在HeLa细胞中得到了表达;小鼠免疫结果表明,用免疫的小鼠都产生了较强的体液免疫和细胞免疫,并且T淋巴细胞增殖数和产生IFN-γ的细胞数和对照组相比显著提高(P<0.05)。间接ELISA试验表明,在免疫第14天抗体水平比对照组明显增高(P<0.05)。结论 成功构建了真核表达质粒pVAXⅠ-P1-2A,并通过小鼠免疫试验发现重组质粒试验组能够诱导产生特异性的体液免疫和细胞免疫应答。     

编码山羊补体C3d与口蹄疫病毒VP1融合蛋白重组质粒的构建及表达

旨在构建含分子佐剂山羊补体C3d基因的O型口蹄疫病毒VP1基因真核表达质粒。克隆山羊C3d基因, 通过linker(G4S)2将3拷贝C3d基因串联; 克隆羊源O型口蹄疫病毒VP1基因, 通过linker(G4S)2与3拷贝C3d基因相连, 构建重组质粒pUC19-VP1-C3d3。将VP1-C3d3融合基因亚克隆入含有分泌表达信号肽tPA序列的pcDNA3.1(+)CMV启动子下游, 构建重组真核表达质粒pcDNA3.1-tPA-VP1-C3d3。在脂质体介导下, 将pcDNA3.1-tPA -VP1-C3d3转染HeLa细胞。间接免疫荧光分析表明, VP1- C3d3在HeLa细胞中获得了瞬时表达, Western blot分析证实转染的阳性细胞能分泌预期大小(133 kD)的融合蛋白。重组质粒pcDNA3.1-tPA-VP1-C3d3为研制以羊补体C3d为分子佐剂的口蹄疫新型疫苗奠定了基础。     

编码山羊补体C3d与口蹄疫病毒VP1融合蛋白重组质粒的构建及表达

旨在构建含分子佐剂山羊补体C3d基因的O型口蹄疫病毒VP1基因真核表达质粒。克隆山羊C3d基因, 通过linker(G4S)2将3拷贝C3d基因串联; 克隆羊源O型口蹄疫病毒VP1基因, 通过linker(G4S)2与3拷贝C3d基因相连, 构建重组质粒pUC19-VP1-C3d3。将VP1-C3d3融合基因亚克隆入含有分泌表达信号肽tPA序列的pcDNA3.1(+)CMV启动子下游, 构建重组真核表达质粒pcDNA3.1-tPA-VP1-C3d3。在脂质体介导下, 将pcDNA3.1-tPA -VP1-C3d3转染HeLa细胞。间接免疫荧光分析表明, VP1- C3d3在HeLa细胞中获得了瞬时表达, Western blot分析证实转染的阳性细胞能分泌预期大小(133 kD)的融合蛋白。重组质粒pcDNA3.1-tPA-VP1-C3d3为研制以羊补体C3d为分子佐剂的口蹄疫新型疫苗奠定了基础。     

共表达O型口蹄疫病毒P1-2A基因和猪白细胞介素18的重组鸡痘病毒的构建

目的:为获得能有效预防O型口蹄疫病毒的重组鸡痘病毒活载体疫苗奠定基础。方法：在O型口蹄疫病毒P1-2A基因上游引入Kozak序列,下游通过Linker与细胞因子IL-18联结,获得P1-2A基因与猪IL-18基因融合表达基因盒P1-2A-IL-18,将该表达基因盒克隆至鸡痘病毒中间转移载体pUTAL-3C中,构建重组鸡痘病毒转移载体质粒pUTAL-3C- P1-2A-IL-18。通过脂质体转染法,将pUTAL-3C- P1-2A-IL-18与鸡痘病毒282E4株共转染鸡胚成纤维细胞（CEF）,通过BrdU三次加压筛选,挑选出单克隆重组病毒株。结果：经RT-PCR和间接免疫荧光法鉴定,证明所筛选的1株重组鸡痘病毒在CEF中能正确表达P1-2A-IL-18基因盒。结论：成功获得了一株共表达O型口蹄疫病毒P1-2A基因和猪白细胞介素18基因的重组鸡痘毒疫苗候选株rFPV-3C-P1-2A-IL-18。     

Use of hi ii-elite inbred hybrids in Agrobacterium-based transformation of maize

Summary Hybrid embryos resulting from crosses between a highly regenerable maize germplasm (Hi II) and certain elite inbreds were treated with Agrobacterium tumefaciens containing the uidA (GUS) and pat genes under the control of different constitutive promoters. Six of the elite inbred lines were derived from a Lancaster background and three were derived from an Iowa Stiff Stalk background. Hybrid embryos from all three Stiff Stalk lines gave transgenic events at various frequencies, two of them at a comparable frequency to that observed with Hi II embryos. Embryos from only one Lancaster/Hi II hybrid were successfully transformed and the frequency was quite low. Additional Lancaster elite inbreds were then tested as a hybrid with Hi II and failed to produce a single transgenic event. The transgenic Hi II/elite events showed many characteristics of ‘hybrid vigor’ including more aggressive rooting, thicker stems, and taller stature than plants derived from Hi II events. The hybrid T₀ plants exhibited excellent tassel development in the greenhouse with abundant pollen shed. Seed set in the greenhouse was significantly (3–5-fold) higher than with Hi II transformats. Attempts to transform embryos derived from self or sibling crosses of the four inbred lines that were successful as hybrids with Hi II did not produce any transgenic events. T₀ plants having ∼50% elite genomic contribution perform nearly as well in the greenhouse as seed-derived elite inbred parents and offer a significantly reduced time line for recombinant protein product development from transgenic plants.     

人胰岛素原基因在大肠杆菌中高效外分泌表达

将胰岛素原基因融合到金色葡萄球菌蛋白Ａ的基因上,构建成大肠杆菌中基因融合的外分泌表达载体。它能高效表达且有效地分泌表达产物。利用亲和层析能方便地从培养液中分离出融合蛋白。融合蛋白经ＣＮＢｒ裂解后,经反相ＨＰＬＣ分析,分离得到具有天然结构的胰岛素原并进行了鉴定。     

口蹄疫病毒VP1基因转化马铃薯及其块茎专一性表达

报道了FMDV VP1基因与马铃薯块茎专一性表达class Ipatatin基因5′区融合,经农杆菌介导导入马铃薯植株,PCR、RT-PCR证实了其整合及转录表达。ELISA结果进一步表明,VP1在转基因马铃薯块茎中具有免疫活性。为探讨在马铃薯块茎中高表达VP1蛋白及进一步开发其作为FMDV口服疫苗生物反应器奠定基础。     

蓖麻毒素A链突变体的设计、表达与活性研究

利用蛋白质结构同源模建并结合表观静电势分析,设计了拟具有生物学活性的蓖麻毒素A链的突变体.将PCR扩增的突变体基因,导入pKK223-3载体中,于大肠杆菌(E.coli)中获得高效、可溶性表达,而且,确证了表达产物具有预期的生物学活性.     

互作蛋白质与复合物亚基的基因表达相关性比较分析

利用在多种应激条件下酵母的基因表达谱数据 ,分别计算互作蛋白质及复合物亚基编码基因的表达相关性。结果发现 ,相对于随机对照组 ,互作蛋白质的编码基因与蛋白质复合物的编码基因表达相关性均显著 (P <0 .0 1) ,即互作蛋白质及复合物亚基有共表达的倾向。通过比较 ,进一步发现蛋白质复合物亚基的基因表达相关性显著高于互作蛋白质的基因表达相关性 (P <0 .0 1) ,这与复合物亚基之间功能联系强于定义不甚确切的互作蛋白之间功能联系现象吻合。     

Co-expression of plastid chaperonin genes and a synthetic plant Rubisco operon in Escherichia coli

It has been suggested that lack of specialized molecular chaperone function(s) in Escherichia coli may account for the fact that although E. coli cells transformed with plant Rubisco genes synthesize the Rubisco subunit polypeptides, the active enzyme fails to assemble. If so, co-expression of plant chaperone and Rubisco genes might permit plant Rubisco assembly in E. coli. Introduction of genes encoding plant chaperonin polypeptides has been shown to enhance the capacity of E. coli to assemble active cyanobacterial Rubisco. We now report that co-expression of plant Rubisco and chaperonin genes affected the solubility and stability of Rubisco large subunit polypeptides, however, neither the assembled oligomeric protein nor Rubisco enzyme activity was detected.     

药用植物分子农场研究进展

植物分子农场可以利用植物生产具有药物用途的重组蛋白或者次生代谢化合物,应用广泛。随着对动植物中具有药物用途的代谢途径的深入解析,代谢途径中关键限速酶或调控蛋白的功能不断被明确,如何选择植物分子农场的底盘植物和遗传改造途径等问题,特别是如何协同提高植物制药产量与品质一直是植物分子农场体系建立中面临的关键科学问题。综述了药用的植物分子农场的最新研究进展,着重介绍了底盘植物的选择与药用植物分子农场的构建策略,以期为提高分子农场应用效果提供有力的科技支撑。     

Production of Plant Made Pharmaceuticals: From Plant Host to Functional Protein

In the last two decades plants have emerged as valuable alternatives to mammalian cells for the production of pharmaceuticals and their potential as expression systems was shown by the commercial availability and acceptance of several plant made therapeuticals in clinical trials. Plants have many advantages over yeast, insect and bacterial expression systems such as the potential to properly fold the expressed proteins and the synthesis of more human-like N-glycans on the proteins. However, several constraints, such as expression yields, downstream processing and structural authenticity, currently limit the widespread use of plant expression systems. In this review, the focus is on the current limitations of plant systems for the production of pharmaceuticals and the possibilities to overcome these obstacles. A comparison is made with insect cell and yeast expression systems. Furthermore, the importance of glycosylation, in particular N-glycosylation for the biological function(s) of therapeutics in the human body will be discussed in detail and an overview of the state of art in the humanization of the N-glycosylation pathway in plants is provided.